ALK and non-small cell lung carcinoma: Crizotinib is the first generation of ALK and ROS1 inhibitor and has been used in the treatment of locally advanced or metastatic NSCLC patients with ALK or ROS1 genes rearrangements in the first-line therapy or after chemotherapy failure.